Skip to content

CD2-Positive Blast Cells, Bone Marrow — Arbitrary Concentration

Published: August 9, 2026Updated: August 17, 2026

Measures CD2-positive blast cells in a bone marrow sample. This marker may be used during leukemia or lymphoma evaluation to characterize abnormal immature immune cells.

Quick summary

["The test shows whether immature cells in the bone marrow carry the CD2 protein, which can help classify certain blood cancers."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 17, 2026Editorial policy

Key facts at a glance

LOINC
51112-1
Short code
CD2 Blasts Mar-aCnc
Synonyms
CD2 Blasts Mar-aCnc
Category
liver
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Ref low
10
Ref high
40
Critical range
— – 500 N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
CPT
84484
SNOMED
302774002
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What is this test?

Blasts are immature cells that normally develop into blood or immune cells. This test looks for blasts that carry CD2, a protein found on many T lymphocytes, in a bone marrow sample.

Why might I need this test?

This test is generally used when leukemia, lymphoma, or another blood disorder is being evaluated. It helps determine the type and origin of abnormal cells when considered with other laboratory and genetic findings.

How is the test performed?

A bone marrow sample is collected and examined for blast cells that express CD2. Testing is commonly performed by flow cytometry, although the laboratory may use another validated method to assess the marker.

How do I prepare for the test?

No special preparation is usually required. Bone marrow aspiration is performed by a trained clinician, often with local anesthetic; follow your healthcare provider's instructions about medications and any procedure-specific precautions.

Reference range

Adult: 10-40 U/LN/A

Specimen: serum

No special preparation required. Avoid fatty meals before the test if possible.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

An increased number of CD2-positive blasts may occur in certain T-cell leukemias and lymphomas. However, CD2 is not specific to one condition, and results must be interpreted with the number and appearance of blasts and findings from other markers, cytogenetics, and clinical evaluation. A positive result alone does not establish a cancer diagnosis.

Short name

CD2-positive blasts

Frequently asked questions

What does a positive CD2 blast result mean?
It means that some immature cells in the sample carry the CD2 protein. This may support a T-cell lineage in a blood cancer, but other testing is needed to determine its exact meaning.
Does this test diagnose leukemia by itself?
No. CD2 is one of several markers used to evaluate leukemia and lymphoma, so the result must be considered alongside the complete laboratory and clinical picture.
Is a bone marrow biopsy always required?
The exact collection method can vary by laboratory and the reason for testing. Many CD2 blast assessments use a bone marrow aspirate, and your clinician will explain which procedure is appropriate.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 17, 2026. · Read our editorial policy